Figure S2.
ERK score in papillary thyroid cancers from TCGA cohort. We compared ERK scores between RET-rearranged (n = 23), BRAF mutant (n = 240), and HRAS/NRAS mutant (n = 48) papillary thyroid cancers. RET-rearranged samples have a significantly higher mean ERK score than either BRAF (P = 0.01) or RAS mutant (P = 5.7 × 10−11) cancers; Student’s t test or ANOVA.

ERK score in papillary thyroid cancers from TCGA cohort. We compared ERK scores between RET-rearranged (n = 23), BRAF mutant (n = 240), and HRAS/NRAS mutant (n = 48) papillary thyroid cancers. RET-rearranged samples have a significantly higher mean ERK score than either BRAF (P = 0.01) or RAS mutant (P = 5.7 × 10−11) cancers; Student’s t test or ANOVA.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal